Royalty Pharma plc RPRX
67.96 USD +0.40 (+0.59%)
Nov 5, 2026, 2:38 PM EST
67.74 Day range 69.77
37.31 52-week range 69.77
- YTD
- +75.88%
- 1 year
- +68.13%
- Market cap
- 39.27B
- Revenue (ttm)
- 2.54B
- Profit margin
- 32.02%
- EPS (ttm)
- 1.53
- Shares out
- 445.28M
- P/E ratio
- 44.42
- Forward P/E
- 11.63
- Dividend
- 0.94 (1.41%)
- Ex-dividend date
- Nov 12, 2026
- YTD return
- +75.88%
- 1-year return
- +68.13%
- Volume
- 3.20M
- Avg volume
- 3.08M
- Open
- 68.00
- Previous close
- 67.56
- Day's range
- 67.74 – 69.77
- 52-week range
- 37.31 – 69.77
- Beta
- 0.36
- Analysts
- Strong Buy
- Price target
- 65.38 (-3.8%)
- Earnings date
- Feb 10, 2027
YTD +29.11 (+74.91%)
Key statistics
- Enterprise value
- 40.64B
- PEG ratio
- 1.55
- Price / sales
- 15.39
- Price / book
- 4.41
- Dividend yield
- 1.42%
- Payout ratio
- 48.40%
- Revenue growth
- 16.50%
- Free cash flow
- -1.20B
- Total cash
- 836.99M
- Total debt
- 8.96B
- Return on equity
- 13.96%
- Short % of float
- 2.92%
- 50-day average
- 60.48
- 200-day average
- 53.49
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 65.38 -3.8% downside
Now 67.96
- Target (low)
- 61.00
- Target (mean)
- 65.38
- Target (high)
- 70.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 10, 2027
Expected Feb 10, 2027. Consensus EPS estimate 1.18.
Financials — quick view
RPRX Revenue — quarterly 674.14M
RPRX Net income — quarterly 17.88M
RPRX EPS — quarterly 0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2027 | Dec 30, 2026 | 1.53 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 1.18 | 1.21 | +0.03 | +2.54% |
| Aug 5, 2026 | Jun 30, 2026 | 1.27 | 1.32 | +0.05 | +3.94% |
| May 6, 2026 | Mar 31, 2026 | 1.21 | 1.30 | +0.09 | +7.44% |
| Feb 11, 2026 | Dec 31, 2025 | 1.29 | 1.46 | +0.17 | +13.18% |
| Nov 5, 2025 | Sep 30, 2025 | 0.994 | 1.17 | +0.18 | +17.71% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 8, 2026 | TD Cowen | main | Buy | Buy |
| Aug 7, 2026 | JP Morgan | main | Overweight | Overweight |
| Jul 13, 2026 | TD Cowen | main | Buy | Buy |
| May 7, 2026 | Citigroup | main | Buy | Buy |
| May 7, 2026 | JP Morgan | main | Overweight | Overweight |
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- royaltypharma.com
News
Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play 
Royalty Pharma Q3 Earnings Call Highlights 
Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript 
Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics 
Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates 
Royalty Pharma Q3 Adj. EPS $1.21 Beats $1.18 Estimate, Sales $690.000M Miss $796.528M Estimate 
Royalty Pharma reports third quarter 2026 results 
Here's How Much $100 Invested In Royalty Pharma 10 Years Ago Would Be Worth Today 
ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test 
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
Your note
Sign in to keep a note on RPRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASSLER BONNIE L | Director | Stock Award(Grant) | Sep 29, 2026 | 79,823 |
| COYNE TERRANCE P | Chief Financial Officer | Sale | Aug 12, 2026 | 0 |
| DESOUZA ERROL B | Director | Stock Award(Grant) | May 12, 2025 | 81,352 |
| ENGELBERT CATHERINE M. | Director | Stock Award(Grant) | Jun 4, 2026 | 55,673 |
| FERNANDEZ HENRY A | Director | Stock Award(Grant) | Jun 29, 2025 | 123,524 |
| HITE CHRISTOPHER | Officer | Sale | Sep 21, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 9.64% | 42,931,597 | 2.90B | Jun 29, 2026 |
| Capital International Investors | 7.92% | 35,273,770 | 2.38B | Jun 29, 2026 |
| Blackrock Inc. | 6.25% | 27,832,977 | 1.88B | Jun 29, 2026 |
| FMR, LLC | 5.51% | 24,513,814 | 1.66B | Jun 29, 2026 |
| State Street Corporation | 2.77% | 12,338,229 | 833.57M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 2.51% | 11,193,657 | 756.24M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEW PERSPECTIVE FUND | 4.34% | 19,337,535 | 1.31B | Sep 29, 2026 |
| Capital Income Builder | 1.67% | 7,427,586 | 501.81M | Sep 29, 2026 |
| Growth Fund of America | 1.52% | 6,747,312 | 455.85M | Sep 29, 2026 |
| MORGAN STANLEY INSTITUTIONAL FUND INC-GROWTH PORTFOLIO | 1.10% | 4,910,932 | 331.78M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.00% | 4,471,210 | 302.07M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Value Equity Trust | 0.95% | 4,232,023 | 285.92M | Jun 29, 2026 |